Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iadademstat and Gilteritinib in FLT3-Mutated R/R AML (FRIDA)
NCT05546580Phase 1Active, not recruiting
- Sponsor
- Oryzon Genomics
- Start
- Nov 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iadademstat in acute myeloid leukemia (AML), sponsored by Oryzon Genomics. Primary endpoints: Adverse Events at 18 months, Laboratory value abnormalities and/or adverse events at 18 months and 9 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
iadademstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05546580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546580.